Arcutis stockholders elect three directors, ratify EY, approve say-on-pay at 2024 annual meeting

Arcutis Biotherapeutics, Inc.

All three Class I director nominees elected: Terrie Curran (77.2M for), Halley Gilbert (75.8M for), Keith R. Leonard Jr. (59.3M for).
Ratification of Ernst & Young as auditor for FY2024 passed with 95,949,963 votes for, 6,661 against.
Non-binding advisory vote on named executive officer compensation approved: 56,906,215 for, 26,716,602 against.
Meeting held June 14, 2024; record date April 22, 2024 with 115,524,989 shares outstanding and entitled to vote.
Broker non-votes of 12,428,038 on director election and say-on-pay proposals, none on auditor ratification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.